* Oncor Inc., of Gaithersburg, Md., acquired Appligene S.A., adeveloper, manufacturer and marketer of molecular geneticproducts in Strasbourg, France, for $2.2 million in cash, notes withan aggregate principal amount of $4.3 million, and 636,000 sharesof Oncor stock.* Agracetus Inc., a subsidiary of W.R. Grace & Co., entered into aresearch, development and manufacturing deal with the Bristol-Myers Squibb Pharmaceutical Group to produce BR96, Bristol-Myers' monoclonal antibody, in transgenic plants.PRP Inc., of Watertown, Mass., has raised $2 million from aprivate placement to help fund clinical development of thecompany's lead product, IPM, an infusible platelet membrane thatserves as a substitute for fresh human platelets. Tullis-DickersonCapital Focus L.P., of Greenwich, Conn., was the lead investor.

(c) 1997 American Health Consultants. All rights reserved.